How to Compile Technical Documentation for Medical Device Registration in Australia

When registering a medical device in Australia (ARTG inclusion), the technical documentation must be organized based on the TGA's risk classification and conformity assessment pathway. Manufacturers should first confirm whether the product is a medical device (including IVDs) and determine its risk level according to TGA classification rules (based on the GHTF framework): Class I (low risk), IIa, IIb, III (high risk), and IVD classification (1–4). The requirements for technical documentation vary significantly by class: Class I devices generally need only to comply with Essential Safety and Performance Requirements (ESPR) and self-declare; Class IIa and above require TGA review or recognition of overseas approvals (e.g., CE, FDA, MDSAP, PAL). Core technical documents include: product description, risk management report (ISO 14971), quality management system certificate (ISO 13485/MDSAP), performance verification and biocompatibility data, clinical evaluation or clinical evidence, labeling and instructions for use, software validation (if applicable), stability testing, sterilization validation, etc. For products already approved under EU CE or US FDA, some materials can be reused but must be adapted to Australian local standards (e.g., AS/NZS standards) and labeling (including local sponsor information). Common risks include: incorrect classification leading to wrong pathway, use of non-recognized evidence, lack of local authorized representative, insufficient clinical evaluation. When compiling the documentation, prioritize building a compliance matrix that matches TGA's 'evidence equivalence' requirements, ensure the technical file is consistent with the ARTG application, and maintain a post-market update mechanism.

Applicable Scenarios and Core Issues

When a medical device company plans to market its product in Australia, the product must be included in the Australian Register of Therapeutic Goods (ARTG) via the TGA. Technical documentation is the core material for registration, and its completeness and compliance directly impact the registration timeline and success rate. This guide applies to all medical device (including IVD) manufacturers, regardless of the registration pathway (self-declaration, review, or mutual recognition). Core issues include: Is the product correctly classified? Do existing technical documents meet TGA requirements? How to adapt the local authorized representative and labeling? How to plan post-market maintenance?

Registration Decision Logic

Step 1: Determine whether the product is a medical device regulated by the TGA. The TGA defines therapeutic goods including medical devices, IVDs, medicines, etc. If the product primarily acts on the surface of or inside the human body and is non-pharmacological, it is usually classified as a medical device.

Step 2: Determine the risk level according to classification rules. Device classification is based on invasiveness, duration of use, contact with the central circulatory system, whether it contains drug-device combinations, etc. IVD classification depends on clinical significance and risk.

Step 3: Determine the registration pathway. Class I low-risk devices can self-declare conformity with ESPR and submit a simple application; Class IIa and above require TGA review or reliance on overseas approvals (e.g., CE, FDA, MDSAP, Singapore HSA).

Step 4: Assess existing systems and technical documents. Companies with ISO 13485 or MDSAP certificates can simplify quality system review; those with CE or FDA approvals can conduct a 'evidence equivalence' analysis to reduce duplicate testing.

Step 5: Confirm the local sponsor. The TGA requires all foreign manufacturers to appoint an Australian local agent as sponsor, responsible for communication with the TGA and post-market obligations.

Step 6: Prepare labeling and instructions for use. Must comply with TGA labeling regulations (e.g., include sponsor information, serial number, UDI requirements, etc.).

Step 7: Compile technical documentation and submit the ARTG application, and simultaneously prepare a post-market vigilance system.

Documentation and Evidence

Technical documents should be organized according to the TGA's 'Medical Device Evidence Framework'. The core document list includes:

• Product description and design features: including intended use, working principle, materials, dimensions, etc.
• Quality management system certificate: ISO 13485 or MDSAP certificate (within validity).
• Risk management report: per ISO 14971, covering the entire lifecycle.
• Clinical evaluation report: for Class IIa and above, typically requires clinical literature review or clinical trial data. The EU MEDDEV 2.7/1 rev.4 can be referenced but must be adapted to TGA requirements.
• Performance verification: includes biocompatibility (ISO 10993), electrical safety (IEC 60601), software validation (IEC 62304), sterilization validation, packaging integrity, stability (accelerated aging), etc.
• Manufacturing information: production process, key suppliers, cleanroom class, etc.
• Labeling and instructions for use: original and translated versions (Chinese/English), must include sponsor name and address.
• Overseas approval certificates: e.g., CE, FDA, MDSAP, PAL, which can be used as evidence to simplify review.
• For IVD products, additional information: clinical sensitivity/specificity analysis, reference interval, calibrator traceability, etc.

All non-English documents must be accompanied by certified translations.

Common Mistakes

• Classification errors: Failure to carefully evaluate according to TGA classification rules (Schedules 2–7), leading to wrong pathway selection. For example, misclassifying a Class IIa device as Class I may cause rejection.
• Use of non-recognized evidence: TGA has additional requirements for some overseas approvals; simply copying CE/FDA reports may result in requests for supplementary local standard testing.
• Lack of local sponsor: Foreign manufacturers failing to appoint or delaying sponsor appointment, making application submission impossible.
• Insufficient clinical evaluation: Class IIb/III devices lacking adequate clinical evidence, or literature review methodology lacking rigor.
• Non-compliant labeling: Missing sponsor information, UDI code not meeting TGA requirements, symbols not explained according to AS/NZS standards.
• Risk management not covering TGA special requirements: e.g., additional assessment for nanomaterials, absorbable materials.
• Missing post-market plan: No plan for periodic safety update reports (PSUR) or vigilance procedures.

Company Preparation Checklist

• Confirm whether the product is a medical device and complete TGA classification (use TGA classification decision tool).
• Appoint an Australian sponsor, sign and notarize the relevant agreement.
• Collect and update the quality management system certificate (ISO 13485/MDSAP).
• Write or update the risk management report (per ISO 14971).
• Compile clinical evaluation report or clinical data (using TGA-recognized approach).
• Complete all applicable performance verification tests (biocompatibility, electrical safety, software, sterilization, stability, etc.).
• Prepare labeling and instructions for use in TGA format (including sponsor information, UDI, symbol explanations).
• If overseas approvals exist, prepare evidence equivalence analysis documents.
• Establish post-market surveillance (PMS) plan and vigilance procedures.
• Submit the ARTG application via the TGA Business Services (eBS) system along with the technical documentation.

AIMEILI Insights

The most common mistakes that companies make when compiling technical documentation for Australian registration are classification and evidence equivalence. Many companies assume that CE or FDA approval can be directly transferred to TGA, but Australia has its own independent standards (e.g., AS/NZS series) and clinical evaluation requirements. Direct reuse often leads to requests for amendments. At the project outset, manufacturers should first confirm classification and perform a gap analysis between existing evidence and TGA requirements; this can save over 50% of rework time. Core technical documents such as risk management, clinical evaluation, and biocompatibility reports can be reused but must be adapted to TGA format and supplemented with local standard differences. Labeling and instructions for use must be fully localized, and sponsor information cannot be omitted. For multi-country registrations, it is recommended to use an MDSAP certificate as the unified quality system evidence, then adjust technical content per country requirements. Control of the certificate is equally important: the sponsor is responsible for subsequent changes and renewal. Companies should clarify the responsibilities with the sponsor to avoid registration interruption due to sponsor changes. Post-market management is a regulatory focus in recent years; it is advisable for companies to establish a dedicated PMS team, submit PSURs regularly, and maintain good communication with the TGA.

Common Follow-up Questions

Q: Does Australia recognize CE (MDD/MDR) or FDA clinical data?

A: The TGA recognizes certain overseas approvals as evidence, but requires evidence equivalence analysis and a description of differences. For example, the CE MDR clinical evaluation report can serve as a basis, but additional local clinical data or literature meeting TGA requirements may be needed. FDA approval is generally considered as coming from a comparable regulatory authority, but it still must be verified against TGA's ESPR. For high-risk devices, the TGA may require independent clinical trials.

Q: Do Class I devices require technical documentation?

A: Yes, but to a lesser extent. While Class I devices can self-declare, they must still retain documents regarding design, manufacturing, risk management, labeling, etc. for audit. The TGA may conduct spot checks, so companies should ensure the technical file is complete and traceable. If a Class I device has measurement function or is sterile, the risk level may increase to Class IIa.

Q: What special requirements exist for IVD products registering in Australia?

A: IVDs are classified into 1–4 classes based on risk; Class 4 (e.g., HIV tests) require TGA review. Technical documentation must include: analytical performance evaluation, clinical performance (sensitivity/specificity), reference intervals, calibrator traceability, stability, etc. Labels must include reagent lot number, expiry date, storage conditions, etc. If using overseas approval evidence, clinical data matching the Australian epidemiology must be provided.

Q: What is the TGA's review timeline after submission of technical documentation?

A: It depends on product classification and pathway. Class I devices: about 1–2 months (formal review only); Class IIa: about 3–6 months; Class IIb/III: about 6–12 months; IVD Class 4: about 8–14 months. If using MDSAP or PAL accelerated pathways, the timeline can be shortened to 3–4 months.

Further Reading

Previous: How to Determine Medical Device Classification for Australian Registration

Next: How to Localize Labeling and Instructions for Use for Australian Medical Device Registration

Recommended: How to Localize Labeling for Canadian Registration, How to Prepare Clinical Evaluation for Canadian Registration, etc.

Content Review and Applicability

Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory authorities, international organizations, standard bodies, and publicly available regulatory information; industry media and project experience serve only as supplementary reference.

Applicability: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace formal requirements, testing conclusions, or legal advice from the target country's regulatory authority.